Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:AMRN

Amarin Q3 2026 Earnings Date & Estimates

Amarin logo
$11.60 +0.09 (+0.78%)
Closing price 10/22/2026 04:00 PM Eastern
Extended Trading
$11.60 0.00 (0.00%)
As of 10/22/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amarin is estimated to report Q3 2026 earnings on Wednesday, October 28, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Amarin in Q3 2026

Amarin is expected to post earnings of -$0.0972 per share on revenue of $43.76 million. Amarin last reported on February 25, 2026, posting $0.01 per share and beating the -$1.27 consensus estimate. Amarin has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0972
Expected Revenue
$43.76 million

Recent Track Record

Last Reported
Q4 2025
Last Quarter EPS
$0.01 (Beat by +$1.28)
Last Quarter Revenue
$49.22 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Amarin Q3 2026 Earnings FAQ

Amarin (NASDAQ:AMRN) is estimated to report Q3 2026 earnings on Wednesday, October 28, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Amarin's Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Amarin to post earnings of -$0.0972 per share for Q3 2026.

The consensus revenue estimate for Amarin is $43.76 million for Q3 2026.

Amarin Earnings Headlines

Amarin (AMRN) Projected to Announce Quarterly Earnings on Wednesday
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148242
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
October 21 at 12:44 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/amarin-report-third-quarter-2026-120000837.html
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
 |  Profits Run (Ad)
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
October 21 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385450/18362/en/amarin-to-report-third-quarter-2026-financial-results-and-host-conference-call-on-october-28-2026.html
Merck KGaA (OTCMKTS:MKKGY) and Amarin (NASDAQ:AMRN) Critical Survey
October 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31122157
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/amarin-amrn-stock-outpacing-medical-195426646.html
See More Amarin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Amarin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amarin and other key companies, straight to your email.

About Amarin

Amarin (NASDAQ:AMRN) (NASDAQ:AMRN) is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular disease. The company’s primary product is icosapent ethyl, an omega-3 fatty acid formulation derived from eicosapentaenoic acid (EPA).

In the United States, icosapent ethyl is marketed as Vascepa and is approved as an adjunct to diet for certain patients with elevated triglyceride levels. It is also approved to reduce the risk of cardiovascular events, such as heart attack and stroke, in specified high-risk adult patients. In Europe, the product is marketed under the name Vazkepa for eligible patients with elevated cardiovascular risk.

Amarin was founded in 1993 and has historically concentrated on cardiovascular-focused drug development and commercialization. The company has pursued regulatory approvals and commercial operations in the United States and selected international markets, including countries in Europe. Its business remains centered on expanding access to and use of icosapent ethyl as part of cardiovascular risk management.

View Amarin Profile
Earnings Tools